Cameron Turtle

Dr. Turtle holds a PhD in Immunology and completed medical training at the University of Sydney, Australia, followed by Fellowships of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. He is an Associate Member of the Anderson Family Endowed Chair for Immunotherapy at Fred Hutchinson Cancer Research Center (FHCRC) and an Associate Professor at the University of Washington (UW) in Seattle, WA.

Dr. Turtle serves as an attending physician on the Hematopoietic Cell Transplant (HCT) Service and the Immunotherapy Service at FHCRC, Seattle Cancer Care Alliance (SCCA), and the UW Medical Center. Additionally, he has a research laboratory in the Clinical Research Division at FHCRC. Dr. Turtle's laboratory is focused on understanding the characteristics of human T cells, their potential utility for tumor immunotherapy, and their role in immune reconstitution after HCT. Dr. Turtle is the Principal Investigator and IND sponsor of several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T cell therapy for patients with B cell malignancies.